| Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 KJ Mavrakis, ER McDonald III, MR Schlabach, E Billy, GR Hoffman, ... Science 351 (6278), 1208-1213, 2016 | 492 | 2016 |
| Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes M Ullah, N Pelletier, L Xiao, SP Zhao, K Wang, C Degerny, S Tahmasebi, ... Molecular and cellular biology, 2008 | 249 | 2008 |
| The tumor suppressor kinase LKB1 activates the downstream kinases SIK2 and SIK3 to stimulate nuclear export of class IIa histone deacetylases DR Walkinshaw, R Weist, GW Kim, L You, L Xiao, J Nie, CS Li, S Zhao, ... Journal of Biological Chemistry 288 (13), 9345-9362, 2013 | 111 | 2013 |
| Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335 CT Lemke, N Goudreau, S Zhao, O Hucke, D Thibeault, M Llinas-Brunet, ... Journal of Biological Chemistry 286 (13), 11434-11443, 2011 | 71 | 2011 |
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations V Subbiah, V Sahai, D Maglic, K Bruderek, BB Touré, S Zhao, R Valverde, ... Cancer discovery 13 (9), 2012-2031, 2023 | 59 | 2023 |
| In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335 L Lagacé, PW White, C Bousquet, N Dansereau, F Dô, M Llinas-Brunet, ... Antimicrobial agents and chemotherapy 56 (1), 569-572, 2012 | 54 | 2012 |
| Use of the fused NS4A peptide− NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A D Thibeault, MJ Massariol, S Zhao, E Welchner, N Goudreau, R Gingras, ... Biochemistry 48 (4), 744-753, 2009 | 35 | 2009 |
| Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3–NS4A proteins MJ Massariol, S Zhao, M Marquis, D Thibeault, PW White Biochemical and biophysical research communications 391 (1), 692-697, 2010 | 28 | 2010 |
| RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations J Casaletto, D Maglic, BB Toure, A Taylor, H Schoenherr, B Hudson, ... Cancer Research 81 (13_Supplement), 1455-1455, 2021 | 20 | 2021 |
| Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2 H Schönherr, P Ayaz, AM Taylor, JB Casaletto, BB Touré, DT Moustakas, ... Proceedings of the National Academy of Sciences 121 (6), e2317756121, 2024 | 18 | 2024 |
| Effects of the G376E and G157D mutations on the stability of yeast enolase–a model for human muscle enolase deficiency S Zhao, BSF Choy, MJ Kornblatt The FEBS Journal 275 (1), 97-106, 2008 | 9 | 2008 |
| 758 Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335 G Kukolj, C Bousquet, N Dansereau, F Do, L Lagace, M Llinas-Brunet, ... Journal of Hepatology, S295, 2010 | 8 | 2010 |
| Bound structure and biochemical mechanism of action of BI 201335, a potent, non-covalent inhibitor of HCV NS3-NS4A protease CT Lemke, S Zhao, N Goudreau, O Hucke, D Thibeault, M Llinàs-Brunet, ... Antiviral Research 1 (86), A20-A21, 2010 | 1 | 2010 |
| Molecular Architecture of Quartet MOZ/MORF Histone Acetyltransferase Complexes (vol 28, pg 6828, 2008) M Ullah, N Pelletier, L Xiao, SP Zhao, K Wang, C Degerny, S Tahmasebi, ... MOLECULAR AND CELLULAR BIOLOGY 29 (3), 972-972, 2009 | 1 | 2009 |
| Suggested searches M Lynch, W Wei, M Pfrender, MM Poon, KI Lorrain, KJ Stebbins, GC Edu, ... Perspective, 2024 | | 2024 |
